Lysaght M J, Nguy N A, Sullivan K
Department of Molecular Pharmacology, Physiology, and Biotechnology, Division of Biology and Medicine, Brown University, Providence, Rhode Island, USA.
Tissue Eng. 1998 Fall;4(3):231-8. doi: 10.1089/ten.1998.4.231.
The contemporary scope of worldwide tissue engineering research and development was estimated by totaling the relevant annual spending and other economic parameters of firms involved the field. Operating expenses allocated to tissue engineering in 1997 exceed $450 million and fund the activities of nearly 2,500 scientists and support personnel. Growth rate is 22.5% per annum. Most activity is centered in the United States. Government spending in this field represents <10% of the total. The aggregate capital value of start-ups that have gone public was approximately $1.7 billion as of January 1, 1998; total capital value of all firms and business units in the field was estimated to be roughly $3.5 billion. The level of investment and valuation represents a remarkable act of faith in the future of a technology yet to produce its first significant revenue-generating product.
通过汇总该领域相关公司的年度支出及其他经济参数,对全球组织工程研究与开发的当前规模进行了估算。1997年分配给组织工程的运营费用超过4.5亿美元,为近2500名科学家及辅助人员的活动提供了资金支持。年增长率为22.5%。大部分活动集中在美国。政府在该领域的支出占总额的比例不到10%。截至1998年1月1日,已上市初创企业的总市值约为17亿美元;该领域所有公司和业务部门的总市值估计约为35亿美元。投资水平和估值体现了对一项尚未产生首个重要创收产品的技术的未来的非凡信心。